National Cancer Institute
11400 Rockville Pike
15 articles with National Cancer Institute
7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, has been awarded a two-year, $2 million Small Business Innovation Research grant from the National Cancer Institute of the U.S. National Institutes of Health.
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
Artelo Biosciences, Inc. announced that the National Cancer Institute has awarded Stony Brook University a $4.2 million grant to advance the development of its fatty acid binding protein 5 inhibitor platform.
New center of excellence aims to improve rates of cervical cancer screening, tobacco cessation
NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™
NeoImmuneTech, Inc. announced that the U.S. Food and Drug Administration has allowed the Center for Cancer Research, National Cancer Institute to proceed with an Investigational New Drug application application for Hyleukin-7™, a long acting T cell amplifier, to begin a clinical trial aiming to enhance the immune reconstitution and vaccine responses in elderly cancer survivors following chemotherapy.
Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting
Flatiron Health announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago.
Gencove announces Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing
Gencove, the leading low-pass sequencing platform announced the receipt of a Phase I grant from the National Cancer Institute under the auspices of the Small Business Innovation Research program of the National Institutes of Health.
Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for Reducing Lung Cancer in High Risk Smokers
The goal of the collaboration with NCI is to successfully file an IND for ATI-1013
Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma
Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019
Industry Experts Offer Insight for Individuals Diagnosed with Late-Stage Illness
Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors
Cellular Biomedicine Group Inc. today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services.
Aethlon Medical, Inc. announced today that the National Cancer Institute (NCI) has awarded the Company a government grant
Voluntis announces that results for eCO, the digital therapeutic it developed for women with ovarian cancer in partnership with AstraZeneca and the National Cancer Institute, have been published in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics.
Tosk, Inc. announced today that it has received a two-year, $2 million Phase II SIBR grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug research and development program, a high priority for the NCI.
Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in PNAS Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined With SVP-Rapamycin
In the PNAS publication, the authors described preclinical work in which SVP-Rapamycin mitigated the formation of inhibitory ADAs to LMB-100 in both naïve mice and mice pre-exposed to LMB-100, resulting in restoration of LMB-100’s anti-tumor activity.
Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute
Under the terms of the CRADA, the NCI will conduct research, including preclinical laboratory studies and a clinical trial, on rigosertib in pediatric cancer associated RASopathies.